Soligenix begins confirmatory phase 3 trial of HyBryte for treatment of cutaneous T-cell lymphoma: Princeton, New Jersey Wednesday, December 18, 2024, 14:00 Hrs [IST] Soligenix, I ...

III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer ...

Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of ...

For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure.

The incidence of adverse events was similar among study groups (placebo = 84.6%, levetiracetam 2000 mg/day = 83.3%, levetiracetam 4000 mg/day = 84.2%) in the double-blind treatment period.

Based on these initial results and the upcoming 52-week readout in the second half 2025, Biomea plans to engage with the FDA to discuss the data. This meeting will provide an opportunity to align with ...

This was a randomised, double-blind, placebo-controlled ... were assessed at baseline and at the last assessment. A study sample size of 84 patients was calculated to provide 80% power with ...

A new study has found that a 400 mg caffeine dose disrupts sleep up to 12 hours before bedtime, yet many people fail to ...

Menarini Group announces positive topline data from pivotal phase 3 BROADWAY & TANDEM trials of Obicetrapib and FDC Obicetrapib with Ezetimibe 10 mg: Florence, Italy Wednesday, De ...

In the initial Phase III study, a 49% treatment response was found in subjects who completed 18 weeks of treatment. Credit: Volha_R / Shutterstock. US-based biotechnology company Soligenix has begun ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Pha ...

Methods: This is a randomized, double-blind, adaptive, seamless, phase 2/3 study (NCT04840485). Eligible patients had active AS (with radiographic evidence fulfilling the modified New York criteria) ...